CARGO Therapeutics eyes one of 2023's largest IPOs in a dull year for listings
Biotech startup CARGO Therapeutics looks to land one of the biggest Nasdaq listings in a barren year for life sciences initial public offerings.
If the blood cancer cell therapy maker can garner enough investor intrigue for an IPO at its proposed midpoint price of $16 per share, then its Wall Street debut would be nearly equal in size to Apogee Therapeutics’ $300 million launch in July but below RayzeBio’s $311 million in September and Acelyrin’s $540 million in May.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.